Dark
Light
Today: June 3, 2024
May 3, 2024
1 min read

Silicon Valley Bank Sells VC Arm to Brookfield and Sequoia

TLDR:

  • Intel announces plans to build two new chip factories in Europe.
  • The investment is part of a larger strategy to boost chip production in the region.

Intel has recently revealed its intention to construct two new chip factories in Europe, as part of a broader effort to increase chip production in the region. The semiconductor company is looking to address the global shortage of chips, which has had ripple effects across various industries, including automotive and consumer electronics.

The decision to build the factories in Europe is seen as a strategic move by Intel to reduce its reliance on Asian suppliers and streamline its supply chain. The move is also expected to create job opportunities and stimulate economic growth in the region.

Intel’s plans come at a time when the European Union is ramping up efforts to boost its own semiconductor manufacturing capabilities. The EU has set ambitious targets to become less dependent on foreign chip suppliers and ensure a stable supply of chips for its industries.

The announcement from Intel has been met with positive reception from European leaders, who see it as a step towards strengthening the region’s position in the global semiconductor market. The investment is expected to enhance Europe’s competitiveness in the tech sector and support innovation and digital transformation.

Overall, Intel’s decision to build two new chip factories in Europe signals a significant commitment to expanding its presence in the region and contributing to the growth of the local semiconductor industry. This move is poised to have far-reaching benefits for both Intel and the European economy as a whole.

Previous Story

SVB Sells VC Arm to Brookfield, Sequoia

Next Story

Fano Labs secures funding for APAC expansion plans

Latest from Blog

Biophta Secures €65M to Fuel Growth and Innovation

TLDR: Biophta, a Paris-based preclinical biotech company, raised €6.5M in seed funding to accelerate trials for treating glaucoma and macular edema. Founded by experienced professionals, the company has developed an innovative technology
Go toTop